Sertaconazole

Summary

Sertaconazole (CHEMBL1201196) is an approved small molecule (ATC D01AC14); indicated across 1 condition including atopic eczema.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AC14 (+1 more)
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 437.8 Da · C20H15Cl3N2OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201196
Name	Sertaconazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	65863
ChEBI	CHEBI:83682
ATC	D01AC14, G01AF19
Molecular formula	C20H15Cl3N2OS
Molecular weight	437.8
InChIKey	JLGKQTAYUIMGRK-UHFFFAOYSA-N

SMILES: C1=CC2=C(C(=C1)Cl)SC=C2COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl

IUPAC name: 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole

ChEBI definition: A member of the class of imidazoles that carries a 2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl group at position 1.

Also known as: Demofix, FI-7045, Sertaconazol, Sertaconazole, sz, SERTACONAZOLE, Sertaconazole nitrateÊ, Sertaconazole nitrateÂ, Sertaconazole nitrate, sertaconazole

Parent form; salt/anhydrous children: CHEMBL1200725

Patent coverage: 2,250 distinct patent families (9,003 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,969 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 22 (assay-derived). Sample: Alpha-2A adrenergic receptor, Androgen receptor, D(1A) dopamine receptor, Thromboxane A2 receptor, Progesterone receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Acetylcholinesterase, Prostaglandin G/H synthase 1, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Mu-type opioid receptor, D(3) dopamine receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, 3’,5’-cyclic-AMP phosphodiesterase 4A, Adenosine receptor A3, Histamine H3 receptor.

Bioactivity

ChEMBL activities: 19 potent at pChembl ≥ 5 of 24 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
AR	7.7	AC50	20.1	nM	CHEMBL_ACT_25203927
ACHE	7	IC50	100	nM	CHEMBL_ACT_26023156
PGR	6.08	AC50	831.1	nM	CHEMBL_ACT_25204860
ADORA3	5.79	AC50	1627	nM	CHEMBL_ACT_25199175
KCNH2	5.77	AC50	1700	nM	CHEMBL_ACT_25118775
DRD3	5.75	AC50	1780	nM	CHEMBL_ACT_25195075
SLC6A3	5.72	AC50	1882	nM	CHEMBL_ACT_25125528
SLC6A4	5.54	AC50	2887	nM	CHEMBL_ACT_25151896
SLC6A2	5.48	AC50	3299	nM	CHEMBL_ACT_25146569
OPRM1	5.45	AC50	3591	nM	CHEMBL_ACT_25158744
IDO1	5.42	IC50	3800	nM	CHEMBL_ACT_22853908
ADRA2A	5.42	AC50	3797	nM	CHEMBL_ACT_25156998
DRD1	5.27	AC50	5392	nM	CHEMBL_ACT_25115779
PTGS1	5.27	AC50	5340	nM	CHEMBL_ACT_25206723
CHRM2	5.2	AC50	6259	nM	CHEMBL_ACT_25196305
P81908	5.13	IC50	7400	nM	CHEMBL_ACT_22853843
PTGS1	5.12	AC50	7680	nM	CHEMBL_ACT_25205793
IDO1	5.08	IC50	8400	nM	CHEMBL_ACT_15016666
CHRM1	5.03	AC50	9445	nM	CHEMBL_ACT_25210705

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
atopic eczema	2	MONDO:0004980	EFO:0000274

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06869681	PHASE4	NOT_YET_RECRUITING	Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea Pedis
NCT01792713	PHASE2	COMPLETED	Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).